Next Article in Journal
Cutaneous Paraneoplastic Syndrome Associated with Anal Squamous Cell Carcinoma: A Rare Presentation of an Uncommon Cancer
Previous Article in Journal
CAMO 2020 Annual Meeting Abstracts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 4
10.3747/co.27.7009
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Meeting Report

Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia

by
S. Dolan
1,
A. Christofides
2,*,
S. Doucette
2,3 and
M. Shafey
3
1
Dalhousie University, St. John, NB, Canada
2
IMPACT Medicom Inc., Toronto, ON, Canada
3
University of Calgary, Calgary, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(4), 420-432; https://doi.org/10.3747/co.27.7009
Submission received: 5 May 2020 / Revised: 4 June 2020 / Accepted: 8 July 2020 / Published: 1 August 2020

Abstract

Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29–30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice.
Keywords: chronic lymphocytic leukemia; untreated disease; treatment-naïve disease; relapsed disease; refractory disease chronic lymphocytic leukemia; untreated disease; treatment-naïve disease; relapsed disease; refractory disease

Share and Cite

MDPI and ACS Style

Dolan, S.; Christofides, A.; Doucette, S.; Shafey, M. Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia. Curr. Oncol. 2020, 27, 420-432. https://doi.org/10.3747/co.27.7009

AMA Style

Dolan S, Christofides A, Doucette S, Shafey M. Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 2020; 27(4):420-432. https://doi.org/10.3747/co.27.7009

Chicago/Turabian Style

Dolan, S., A. Christofides, S. Doucette, and M. Shafey. 2020. "Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia" Current Oncology 27, no. 4: 420-432. https://doi.org/10.3747/co.27.7009

APA Style

Dolan, S., Christofides, A., Doucette, S., & Shafey, M. (2020). Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia. Current Oncology, 27(4), 420-432. https://doi.org/10.3747/co.27.7009

Article Metrics

Back to TopTop